Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.
Chief Executive Officer Dr. Christian Itin said the company had a “very good first quarter,” with $26.2 million in revenue booked. He said Autolus is seeing “nice traction building” in the U.S. and in the early stages of its U.K. launch, where more than 10 centers are already active under the NHS access program.
